Search for: All records

Objective:To discuss the potential for adverse consequences that could arise from the quest to prolong the functional life span of the human ovary. Methods:A series of arguments are presented that: (a) question the dogma that monthly ovulatory menstrual cycles are critical for women’s health; (b) review adverse consequences of decades of menstrual cyclicity; (c) review the evidence for a longevity benefit of ovarian steroid hormone treatment after the age at natural menopause has been achieved; and (d) utilize a mathematical model of ovarian follicle loss over time to raise the possibility that current strategies directed at delaying menopause might well backfire and in fact cause a woman to have a prolonged menopause transition. Results:Regular, monthly menstrual cycles have not been the reality for women for most of history. Rather, when not pregnant, lactational amenorrhea and nutritionally based hypothalamic amenorrhea were the norm for reproductive-aged women. Moreover, monthly menstrual cycles cause substantial morbidity for women during their reproductive years. Providing steroid hormones after menopause has failed to demonstrate an increase in the female life span. Restoring ovarian follicles either surgically or medically has a high probability of causing women to spend more years of life in the menopause transition. Conclusions:Strategies to prevent or delay menopause would benefit from careful consideration of unintended consequences as they are implemented. Directing treatment trials to those with the greatest chance for benefit should be undertaken before adopting this type of treatment for a broader population. 

Abstract BACKGROUNDWomen are increasingly choosing to delay childbirth, and those with low ovarian reserves indicative of primary ovarian insufficiency are at risk for sub- and infertility and also the early onset of menopause. Experimental strategies that promise to extend the duration of ovarian function in women are currently being developed. One strategy is to slow the rate of loss of existing primordial follicles (PFs), and a second is to increase, or ‘boost’, the number of autologous PFs in the human ovary. In both cases, the duration of ovarian function would be expected to be lengthened, and menopause would be delayed. This might be accompanied by an extended production of mature oocytes of sufficient quality to extend the fertile lifespan. OBJECTIVE AND RATIONALEIn this work, we consider how slowing physiological ovarian aging might improve the health and well-being of patients, and summarize the current state-of-the-art of approaches being developed. We then use mathematical modeling to determine how interventions are likely to influence the duration of ovarian function quantitatively. Finally, we consider efficacy benchmarks that should be achieved so that individuals will benefit, and propose criteria that could be used to monitor ongoing efficacy in different patients as these strategies are being validated. SEARCH METHODSCurrent methods to estimate the size of the ovarian reserve and its relationship to the timing of the menopausal transition and menopause were compiled, and publications establishing methods designed to slow loss of the ovarian reserve or to deliver additional ovarian PFs to patients were identified. OUTCOMESWe review our current understanding of the consequences of reproductive aging in women, and compare different approaches that may extend ovarian function in women at risk for POI. We also provide modeling of primordial reserve decay in the presence of therapies that slow PF loss or boost PF numbers. An interactive online tool is provided that estimates how different interventions would impact the duration of ovarian function across the natural population. Modeling output shows that treatments that slow PF loss would need to be applied as early as possible and for many years to achieve significant delay of menopause. In contrast, treatments that add additional PFs should occur as late as possible relative to the onset of menopause. Combined approaches slowing ovarian reserve loss while also boosting numbers of (new) PFs would likely offer some additional benefits in delaying menopause. WIDER IMPLICATIONSExtending ovarian function, and perhaps the fertile lifespan, is on the horizon for at least some patients. Modeling ovarian aging with and without such interventions complements and helps guide the clinical approaches that will achieve this goal. REGISTRATION NUMBERNot applicable. 

Developmental endocrinology is a fascinating and mature field that investigates the role of hormones in the growth and development of living organisms. Hormones influence various life processes, from the earliest stages of life to old age. As a study of bodily communication at the cellular and humoral level, it integrates all aspects of health. As such, women’s healthcare and research find a comfortable home here. As a multidisciplinary field, developmental endocrinology draws on knowledge and uses tools from several other areas, including developmental biology, genetics, physiology, and neuroscience. All these approaches unlock new insights into interactions involving growth and development, reproduction, metabolism, and behavior, all as influenced by hormonal action. Developmental endocrinology will continue to shed light on how hormones impact health and disease across the lifespan, and its enormous translational value makes it a crucial area of research that supports the health of women. Despite advances in the field, it is important to acknowledge that there has been a shortfall in investment in women’s health overall, including underinvestment in research in the specific context of women’s reproduction. 

Ovarian aging in women can be described as highly unpredictable within individuals but predictable across large populations. We showed previously that modeling an individual woman’s ovarian reserve of primordial follicles using mathematical random walks replicates the natural pattern of growing follicles exiting the reserve. Compiling many simulations yields the observed population distribution of the age at natural menopause (ANM). Here, we have probed how stochastic control of primordial follicle loss might relate to the distribution of the preceding menopausal transition (MT), when women begin to experience menstrual cycle irregularity. We show that identical random walk model conditions produce both the reported MT distribution and the ANM distribution when thresholds are set for growing follicle availability. The MT and ANM are shown to correspond to gaps when primordial follicles fail to grow for 7 and 12 days, respectively. Modeling growing follicle supply is shown to precisely recapitulate epidemiological data and provides quantitative criteria for the MT and ANM in humans. 

Abstract Women are born with hundreds of thousands to over a million primordial ovarian follicles (PFs) in their ovarian reserve. However, only a few hundred PFs will ever ovulate and produce a mature egg. Why are hundreds of thousands of PFs endowed around the time of birth when far fewer follicles are required for ongoing ovarian endocrine function and only a few hundred will survive to ovulate? Recent experimental, bioinformatics, and mathematical analyses support the hypothesis that PF growth activation (PFGA) is inherently stochastic. In this paper, we propose that the oversupply of PFs at birth enables a simple stochastic PFGA mechanism to yield a steady supply of growing follicles that lasts for several decades. Assuming stochastic PFGA, we apply extreme value theory to histological PF count data to show that the supply of growing follicles is remarkably robust to a variety of perturbations and that the timing of ovarian function cessation (age of natural menopause) is surprisingly tightly controlled. Though stochasticity is often viewed as an obstacle in physiology and PF oversupply has been called “wasteful,” this analysis suggests that stochastic PFGA and PF oversupply function together to ensure robust and reliable female reproductive aging. 

Mechanism(s) that control whether individual human primordial ovarian follicles (PFs) remain dormant, or begin to grow, are all but unknown. One of our groups has recently shown that activation of the Integrated Stress Response (ISR) pathway can slow follicular granulosa cell proliferation by activating cell cycle checkpoints. Those data suggest that the ISR is active and fluctuates according to local conditions in dormant PFs. Because cell cycle entry of (pre)granulosa cells is required for PF growth activation (PFGA), we propose that rare ISR checkpoint resolution allows individual PFs to begin to grow. Fluctuating ISR activity within individual PFs can be described by a random process. In this article, we model ISR activity of individual PFs by one-dimensional random walks (RWs) and monitor the rate at which simulated checkpoint resolution and thus PFGA threshold crossing occurs. We show that the simultaneous recapitulation of (i) the loss of PFs over time within simulated subjects, and (ii) the timing of PF depletion in populations of simulated subjects equivalent to the distribution of the human age of natural menopause can be produced using this approach. In the RW model, the probability that individual PFs grow is influenced by regionally fluctuating conditions, that over time manifests in the known pattern of PFGA. Considered at the level of the ovary, randomness appears to be a key, purposeful feature of human ovarian aging.